ITM Isotope Technologies Munich has secured an exclusive global license for the clinical and commercial development of Debiopharm’s cancer imaging and treatment pair ITM-91/ITM-94D.
Formerly known as Debio 0228/0328, ITM-91/ITM-94D targets a surface protein expressed on solid tumors. ITM-91 is a lutetium-177-labeled radioligand therapeutic compound and ITM-94D is a gallium-68-labeled imaging agent. The pair is being investigated in the phase I/II clinical trial in patients with clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.
Under the agreement, Debiopharm will receive payments of approximately $331 million, as well as commercial milestones and royalties on potential future sales, ITM said.
